UK Contraceptive Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 80 Pages I Mordor Intelligence
UK Contraceptive Devices Market Analysis
The UK contraceptive devices market reached USD 652.38 million in 2025 and is forecast to climb to USD 873.94 million in 2030, advancing at a 6.02% CAGR. This expansion reflects the National Health Service's (NHS) preventive-care emphasis, a regulatory climate that rewards product safety, and persistent demographic trends that sustain demand for reliable birth-control technologies. Rising sexually transmitted infection (STI) rates, notably the 85,223 gonorrhoea diagnoses recorded in 2023, keep dual-protection methods such as condoms squarely in focus.The Medicines and Healthcare products Regulatory Agency (MHRA) intensified post-market surveillance rules in 2024, raising entry barriers yet reinforcing end-user confidence in device quality. Meanwhile, the January 2024 policy that allows pharmacists to dispense oral contraceptives without a general-practitioner consultation has accelerated over-the-counter (OTC) and online sales channels. Together, these forces position the UK contraceptive devices market for steady medium-term growth despite public-sector budget constraints and periodic supply bottlenecks.
UK Contraceptive Devices Market Trends and Insights
High Prevalence of STIs & Rising Awareness
England alone logged 401,800 STI cases in 2023, a 4.7% year-on-year increase, keeping barrier methods at the centre of preventive policy. Gonorrhoea cases have reached their highest level since 1918, while 52 antibiotic-resistant strains had been identified by mid-2025. Public-health messaging now frames condoms as dual-function tools that curb both pregnancies and infections, boosting unit volumes in the UK contraceptive devices market. National surveillance also shows that 46% of new STI cases occur in the 15-24 age bracket, prompting age-specific outreach campaigns.Local authorities, citing resource strain, increasingly promote self-care and home-delivery condom programmes, reinforcing a preventive mindset.
Increasing Unintended Pregnancies & UK-Wide Public-Health Drives
UK reproductive-health profiles show long-acting reversible contraception (LARC) uptake among women under 25 rising from 27.6% in 2019 to 36.2% in 2023, yet overall utilisation remains below pre-pandemic levels. Scotland's bridging-contraception initiative delivers three-month supplies of progestogen-only pills through pharmacies, eliminating appointment delays and widening access. Parallel educational reforms mandate comprehensive relationships and sex education in schools, ensuring that the emerging adult cohort enters the UK contraceptive devices market with higher baseline awareness parliament.uk. Together, these programmes create latent demand for a diverse product mix that extends beyond condoms to LARCs, rings, and diaphragms.
Device-Related Adverse Effects & Discontinuation
Heightened media attention on safety concerns, such as the meningioma risk linked to prolonged use of certain injectable progestogens, has raised discontinuation rates for some methods. The MHRA now obliges manufacturers to submit granular adverse-event reports within strict timelines, elevating compliance costs but also improving post-market data transparency. Professional societies such as the British Society of Urogynaecology actively encourage clinicians to report device complications, further sensitising the public to possible side effects. While long-acting progestogen therapies can reduce repeat interventions, risk-benefit calculations have become more nuanced, leading some women to revert to condoms or non-hormonal methods.
Other drivers and restraints analyzed in the detailed report include:
Government Support for Reproductive and Family-Planning Services / Consumer Shift Toward OTC & E-Pharmacy Fulfilment / NHS Funding Pressure Causing Supply Bottlenecks /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
The segment generated 55.89% of UK contraceptive devices market revenue in 2024, underscoring condoms' strong dual-protection value proposition and extensive retail availability. The UK contraceptive devices market size for condoms amounted to USD 365.2 million in 2025, and volumes stay resilient as STI control remains a public-health priority. Intra-uterine devices (IUDs) are the fastest-growing line, advancing at a 9.03% CAGR to 2030, bolstered by extended wear times and favourable cost-utility ratios. Bayer's Mirena and Kyleena systems now carry eight-year licences, a milestone that reduces replacement frequency and elevates lifetime adherence. Regulatory confidence also surfaced in 2024 when the Levosert hormonal IUS secured its own eight-year extension, signalling a high safety-efficacy threshold for hormonal platforms.
Innovations in non-hormonal technology add breadth to the category. The contoured Caya diaphragm, already registered in nearly 40 countries, demonstrates high acceptability in pilot studies and offers a silicone-free alternative for latex-sensitive users. Research published in Advanced Materials shows promise for stimuli-responsive hydrogels that produce reversible fallopian-tube occlusion, hinting at future patient-controlled sterilisation modalities. Vaginal rings are evolving beyond hormone-delivery systems; Bayer is co-developing a ferrous-gluconate-based ring that impedes sperm motility without altering hormonal balance. These R&D pipelines widen the technology mix, enabling manufacturers to address both safety concerns and emerging lifestyle preferences.
UK Contraceptive Devices Market Report is Segmented by Type (Condoms, Diaphragms & Cervical Caps, Vaginal Rings, Intra Uterine Devices, Implants & Injectables, Spermicidal Devices and Other Types), Gender (Male and Female) and Distribution Channel (NHS & Community Sexual-Health Clinics, Retail Pharmacies, Online Pharmacies & E-Commerce, and More). The Market Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
Bayer / The Cooper Companies / Pfizer / Organon / Gedeon Richter Plc. / Reckitt Benckiser Group plc (Durex) / Pregna International Ltd. / Karex Berhad / Okamoto Industries Inc. / Femcap Inc / Lifestyle Healthcare Pte Ltd / Pasante Healthcare Ltd / Relarc BV / LTC Healthcare / Skins Sexual Health / KESSEL medintim GmbH /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 High prevalence of STDs & rising awareness
4.2.2 Increasing unintended pregnancies & UK-wide public-health drives
4.2.3 Government support for Reproductive and Family Planning services
4.2.4 Consumer shift toward OTC & e-pharmacy fulfilment
4.2.5 Growth Demand for LARCs and Innovative Devices
4.2.6 Integration of Contraception with Digital Health Platforms
4.3 Market Restraints
4.3.1 Device-related adverse effects & discontinuation
4.3.2 Sociocultural resistance among specific faith & ethnic groups
4.3.3 NHS funding pressure causing supply bottlenecks
4.3.4 Regulatory and Privacy Challenges Amid Digital Contraceptive Solutions
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technology Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers
4.7.2 Bargaining Power of Buyers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Intensity of Competitive Rivalry
5 Market Size and Growth Forecasts (Value-USD)
5.1 By Type
5.1.1 Condoms
5.1.2 Diaphragms & Cervical caps
5.1.3 Vaginal Rings
5.1.4 Intra-Uterine Devices
5.1.5 Implants & Injectables
5.1.6 Spermicidal Devices
5.1.7 Other Types
5.2 By Gender
5.2.1 Male
5.2.2 Female
5.3 By Distribution Channel
5.3.1 NHS & Community Sexual-Health Clinics
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies & e-commerce
5.3.4 Supermarkets & Convenience Stores
5.3.5 Others (Charities, Youth Centres)
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.3.1 Bayer AG
6.3.2 Cooper Surgical Inc.
6.3.3 Pfizer Inc.
6.3.4 Organon & Co.
6.3.5 Gedeon Richter Plc.
6.3.6 Reckitt Benckiser Group plc (Durex)
6.3.7 Pregna International Ltd.
6.3.8 Karex Berhad
6.3.9 Okamoto Industries Inc.
6.3.10 Femcap Inc
6.3.11 Lifestyle Healthcare Pte Ltd
6.3.12 Pasante Healthcare Ltd
6.3.13 Relarc BV
6.3.14 LTC Healthcare
6.3.15 Skins Sexual Health
6.3.16 KESSEL medintim GmbH
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.